welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Stem Cell Therapy in Duchenne Muscular Dystrophy
study id #: NCT02241434
condition: Duchenne Muscular Dystrophy
The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.
intervention: Stem Cell
mechanism of action: Stem cell therapy to promote cellular regeneration
last updated: November 21, 2018
start date: January 2009
estimated completion: June 2016
phase of development: Phase 1
- Manual Muscle Testing [ Time Frame: 1 year ]
- Brooke and Vignos Scale [ Time Frame: 1 year ]
• age group of 3-25 years
• Duchenne muscular dystrophy diagnosed on the basis of clinical presentation
• presence of respiratory distress
• presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
• acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
• pregnancy or breastfeeding
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with co...Duchenne muscular dystrophy (DMD) is one...
Treatment Effect of Tamoxifen on Patients With DMDDuchenne muscular dystrophy (DMD) is a p...
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body MyositisThe investigators are performing a gene ...
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (D...This research study is designed to evalu...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
UCLA’s Duchenne Muscular Dystrophy Research Funded by a Stem Cell AgencyScientists at the UCLA Eli and Edythe Br...